Marinus Pharma CS (MRNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 21,467 | 27,181 | 33,531 | 37,530 | 19,531 |
| Marketable Securities | 24,902 | 24,839 | 19,861 | 5,435 | 744 |
| TOTAL | $47,407 | $53,718 | $54,370 | $43,547 | $20,959 |
| Non-Current Assets | |||||
| PPE Net | 1,280 | 1,315 | 1,338 | 1,172 | 1,136 |
| Investments And Advances | 0 | 0 | 4,964 | 19,938 | 0 |
| TOTAL | $1,280 | $1,315 | $6,302 | $21,110 | $1,136 |
| Total Assets | $48,687 | $55,033 | $60,672 | $64,657 | $22,095 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,294 | 797 | 927 | 634 | 1,161 |
| Accrued Expenses | 2,266 | 997 | 1,617 | 1,796 | 1,016 |
| TOTAL | $3,560 | $1,794 | $2,544 | $2,430 | $5,674 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 107 | 114 | 120 | 127 | 132 |
| TOTAL | $107 | $114 | $120 | $127 | $132 |
| Total Liabilities | $3,667 | $1,908 | $2,664 | $2,557 | $5,806 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 10,131 | 10,130 | 10,130 | 10,108 | 6,519 |
| Common Shares | 41 | 41 | 41 | 40 | 23 |
| Retained earnings | -160,231 | -150,726 | -144,727 | -139,989 | -135,819 |
| Other shareholders' equity | -69 | -107 | -96 | -18 | 0 |
| TOTAL | $45,020 | $53,125 | $58,008 | $62,100 | $16,289 |
| Total Liabilities And Equity | $48,687 | $55,033 | $60,672 | $64,657 | $22,095 |